Key result
A lead RNA aptamer, #FP-10, identified via the CRISmers screening platform, demonstrated potent pan-coronavirus neutralization activity against multiple SARS-CoV-2 variants and alphacoronaviruses.
Why the study?
A series of coronavirus outbreaks emphasized the necessity to develop pan-coronavirus therapeutics.
The CRISmers screening platform successfully identified an RNA aptamer (#FP-10) with broad-spectrum neutralizing activity against multiple coronaviruses, highlighting its potential as a pan-coronavirus therapeutic candidate.
Hypothesis-generating for pan-coronavirus aptamer strategies; leaves open clinical translation pending validation.
A series of coronavirus outbreaks emphasize the necessity to develop pan-coronavirus therapeutics. Previously, the CRISmers system is developed, a Clustered Regularly Interspaced Short Palindromic Repeats/CRISPR-associated proteins (CRISPR/Cas)-mediated cellular screening platform for the identification of RNA aptamers. In this study, CRISmers are applied to target the fusion peptide (FP) of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), a conserved region across coronavirus genera, with E.coli serving as the screening host. From this approach, a lead aptamer, #FP-10 is identified, which demonstrates potent pan-coronavirus neutralization activity against multiple SARS-CoV-2 variants and alphacoronaviruses (HCoV-229E and HCoV-NL63), demonstrating its potential for development into a broad-spectrum therapeutic candidate.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2025) studied Coronavirus infection. RNA aptamer #FP-10 was evaluated on Pan-coronavirus neutralization activity. A lead RNA aptamer, #FP-10, identified via the CRISmers screening platform, demonstrated potent pan-coronavirus neutralization activity against multiple SARS-CoV-2 variants and alphacoronaviruses.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: